NDA 020256 · Shine
Neurolite
Technetium Tc-99m Bicisate Kit · Injection
NovelLast checked: Nov 19, 2026Latest source record: Feb 3, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1994
Nov 23, 1994
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
23
11 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 10, 2026.
INDICATIONS NEUROLITE ® single photon emission computerized tomography (SPECT) is indicated as an adjunct to conventional CT or MRI imaging in the localization of stroke in patients in whom stroke has already been diagnosed. NEUROLITE ® is not indicated for assessment of functional viability of brain tissue. Also, NEUROLITE ® is not indicated for distinguishing between stroke and other brain lesions.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 23, 1994 Original approval · Type 1 - New Molecular Entity
1 products under this application
- NEUROLITE · TECHNETIUM TC-99M BICISATE KIT N/A · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Bicisate Kit" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective8
- product preparation error5
- radioisotope scan abnormal3
- adverse event1
- anaemia1
- anaphylactic shock1
- arthralgia1
- blood pressure decreased1
- chills1
- cholecystitis1
- cholelithiasis1
- cold sweat1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2007 | 3 |
| 2008 | 1 |
| 2010 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 4 |
| 2025 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- 99mTc-bicisate reliably images CBF in chronic brain diseases but fails to show reflow hyperemia in subacute stroke: report of a multicenter trial of 105 cases comparing 133Xe and 99mTc-bicisate (ECD, neurolite) measured by SPECT on same day.
Lassen NA, Sperling B · J Cereb Blood Flow Metab 1994 · Clinical Trial, Comparative Study
- 99mTc-bicisate (neurolite) SPECT brain imaging and cognitive impairment in dementia of the Alzheimer type: a blinded read of image sets from a multicenter SPECT trial.
Waldemar G, Walovitch RC, Andersen AR, et al. · J Cereb Blood Flow Metab 1994 · Clinical Trial, Multicenter Study
- The role of single photon emission computed tomography brain imaging with 99mTc-bicisate in the localization and definition of mechanism of ischemic stroke.
Brass LM, Walovitch RC, Joseph JL, et al. · J Cereb Blood Flow Metab 1994 · Clinical Trial, Multicenter Study
- Evaluation of brain perfusion with technetium-99m bicisate single-photon emission tomography in patients with depressive disorder before and after drug treatment.
Kocmur M, Milcinski M, Budihna NV · Eur J Nucl Med 1998 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Shine
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.